Released : April 20, 2017 18:00 RNS Number : 9189C MaxCyte, Inc. 20 April 2017 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO US PERSONS (AS DEFINED IN REGULATION S UNDER
Released : April 13, 2017 13:00 RNS Number : 4800C MaxCyte, Inc. 13 April 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of AGM and 2016 Annual Report and Accounts Maryland, USA - 13 April 2017: MaxCyte (LSE: MXCT), a US-based global company dedicated to driving the acceleration
Released : March 31, 2017 12:40 RNS Number : 1963B MaxCyte, Inc. 31 March 2017 THIS ANNOUNCEMENT (INCLUDING ITS APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO US PERSONS (AS
Released : March 31, 2017 07:00 RNS Number : 0996B MaxCyte, Inc. 31 March 2017 THIS ANNOUNCEMENT (INCLUDING ITS APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO US PERSONS (AS
Released : March 20, 2017 07:00 RNS Number : 8799Z MaxCyte, Inc. 20 March 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Reports Final Results for Year Ended 31 December 2016 Consistent top-line growth with 32% increase in revenues and gross margins approaching 90% Maryland,
Released : March 14, 2017 07:00 RNS Number : 3349Z MaxCyte, Inc. 14 March 2017 MaxCyte, Inc. ("MaxCyte") CRISPR THERAPEUTICS/CASEBIA OBTAIN MAXCYTE COMMERCIAL LICENSE CRISPR Therapeutics and Casebia obtain commercial rights to MaxCyte's cell engineering platform to develop
Released : March 02, 2017 07:00 RNS Number : 3008Y MaxCyte, Inc. 02 March 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte to Present Pre-Clinical CARMA Data at AACR Meeting - In vivo research demonstrates potential of novel, proprietary, CARMA product candidate for use
Released : March 01, 2017 07:00 RNS Number : 0875Y MaxCyte, Inc. 01 March 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of Full Year Results Maryland, USA - 1 March 2017: MaxCyte (LSE: MXCT), a US-based global company dedicated to accelerating the discovery, development,
Released : January 24, 2017 07:00 RNS Number : 9020U MaxCyte, Inc. 24 January 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Consecutive 30 percent year-on year revenue growth Maryland, USA - 24 January 2017: MaxCyte (LSE: MXCT), the developer and supplier of cell
Gaithersburg, MD, January 16, 2017 – MaxCyte®, Inc., developer and supplier of cell engineering products and technologies to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, announced today that Madhusudan V.
